Sunshine Biopharma Inc. reported positive topline results from its Phase 2 trial of SBFM-PL4, an anti-cancer drug candidate. The study met its primary endpoints and showed a statistically significant improvement in progression-free survival among patients with a specific type of advanced pancreatic cancer.
The company plans to meet with the FDA to discuss a path forward for a Phase 3 trial. SBFM shares surged in pre-market trading following the announcement.
The results mark a milestone for the small-cap biotech and could support a pivotal study. The market reaction reflects optimism about the drug’s commercial potential in an area of high unmet need.